Tumor-associated antigen recognition by innate immunity

Tumor-associated antigen recognition by innate immunity refers to how *innate immune cells and receptors* detect antigens derived from tumor cells. This recognition occurs via pattern recognition receptors (PRRs) such as Toll-like receptors, RIG-I-like receptors, and especially the STING pathway, which senses tumor-derived DNA or stress signals. Such recognition stimulates pro-inflammatory cytokine release, type I interferon production, and the activation of adaptive immune responses, particularly CD8+ T cell responses against tumor antigens[1][2][3][4]. While this process is fundamental in tumor immunosurveillance and the efficacy of cancer immunotherapies, it is not itself an individual biomolecular entity but a network of innate immune mechanisms.

Other names

Innate immune tumor antigen recognitionInnate immune cancer immunosurveillanceInnate immune sensor of tumor antigens

Activation of innate immune cells (e.g., NK cells, dendritic cells); Upregulation of pattern recognition receptor signaling (e.g., STING pathway triggering IFN production)